For many, dividend investing is all about the yield. They search for stocks that offer high yields, thinking that’s enough to ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award a seed grant of $610,000 to Justus ...

$60,000 of ABBVIE INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "International tax issues and pharmaceutical ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

On Friday, Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy ...

A global commission has proposed a fundamental change to the way obesity is defined and diagnosed. If the change is ...

Lara Walsh is a Chicago-based writer and editor who covers all things fashion, celebrity, pop culture, travel, and food. When she’s not avidly planning her next trip, she’s writing posts for ...